Lucence: Lighting up the Future of Cancer Care

Lucence: Lighting up the Future of Cancer Care

Journal article

1 article.

One in three people will get cancer in their lifetime. This stark statistic makes early detection of cancer - when the disease is more treatable and curable - a “must.” A hyper-sensitive blood test developed by Lucence, a precision oncology company based in Singapore and the USA, promises to make early detection a reality. Through its ground-breaking technology, Lucence is working to improve cancer care and cure rates through a simple blood test. Its ultra-sensitive liquid biopsy tests make it possible to profile cancer accurately, rapidly and affordably with a single blood draw, allowing physicians to make better treatment decisions and improve health outcomes. Dr. Min-Han Tan, Founder and CEO of Lucence, talks to WIPO Magazine about his company’s commitment to saving the lives of cancer patients around the world through earlier detection of the disease.

Geneva, Switzerland : World Intellectual Property Organization, 2023.

eng

WIPO Publications > English
WIPO Magazine